ARUP Newsroom

The U.S. District Court for the Eastern District of Texas today struck down the FDA’s final rule to regulate laboratory-developed tests.

ARUP CEO Andy Theurer leads a group of university students through ARUP’s Automated Core Laboratory.

Jonathan Genzen, MD, PhD, MBA, ARUP’s chief medical officer and senior director of governmental affairs, along with three coauthors, created a detailed resource summarizing existing federal laws and regulations in the context of anatomic pathology.

Benjamin Bradley, MD, PhD, medical director of the ARUP Institute for Research and Innovation in Infectious Disease Genomic Technologies, High Consequence Pathogen Response, Virology, and Molecular Infectious Diseases, participated in a media briefing about the measles virus with the College of American Pathologists.

Research highlights will include applications of RNA sequencing, long-read whole genome sequencing, and cytogenetics in the identification of rare and undiagnosed diseases, confirmation of novel variants, the curation of standardized reports for pharmacogenetics testing, and more.

The robotic arm removes the wet-mount specimen slide in preparation for scanning. Once scanned, the image will be screened via artificial intelligence (AI) for evidence of ova and parasites.

Tracy I. George, MD, ARUP Laboratories’ chief scientific officer and president of the Innovation Business Unit, detailed ARUP’s commitment to cutting-edge diagnostic research during a Rare Disease Day event hosted at Recursion on February 27. The podium featured a zebra, the mascot of people with rare diseases.